BIBA Medical Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News Neuro News CX Symposium ilegx BIBA Med PA BIBA Research
Members login
Password reminder  

RegisterEdit your account | View you account

CX Symposium
CX Home
 
CX Product News

Pluromed launches LeGoo Internal Vessel Occluder for clampless vascular surgery

For a long time there has been a need for a simpler, atraumatic method to control bleeding during surgery. Conventional tools such as clamps, occlusion balloons or vessel loops can fail to provide a completely bloodless field, can be cumbersome to use, are potentially traumatic to the vessels, or simply cannot be used, for example, in cases of extensive calcification.


At Charing Cross, Pluromed is launching LeGoo Internal Vessel Occluder, the first ever fully reversible atraumatic gel plug to replace clamps, occlusion balloons or vessel loops in vascular surgery; lung, kidney, and liver surgery; and organ transplant. LeGoo is CE-Marked and is already in clinical use in many leading hospitals in Europe.


LeGoo is used predominantly in peripheral bypass (Fem-Tib, Fem-Pop, Fem-Fem, etc) and arteriovenous fistula for hemodialysis patients. LeGoo is also used in the heart during off-pump and on-pump coronary artery bypass surgery. LeGoo is very resistant to blood flow even in quite large arteries (up to and including the iliac), yet the plug reopens in seconds when touched with sterile ice or dissolved with cold saline. 


LeGoo is made of a biocompatible, aqueous, reverse thermosensitive polymer. At lower temperatures, LeGoo exists as a liquid. At body temperature, LeGoo rapidly changes to a viscous gel in a reversible phase change. When injected into a blood vessel, LeGoo forms an occluding plug at the injection site. The occlusion is designed to last for the duration of an average anastomosis, though subsequent injections can prolong the duration of occlusion if needed, and flow can be fully restored instantly by cooling the vessel and dissolving the gel. Once dissolved, it can never re-solidify and there has been no evidence in clinical or preclinical experience of any tissue damage related to a LeGoo plug. LeGoo has been extensively studied for microvascular reactivity and its inability to cause micro-infarcts. LeGoo is neither absorbed nor metabolised: it passes through the microcirculation and is excreted in urine.


Because LeGoo conforms to any vascular geometry, the surgeon can ‘clamp’ without clamping and achieve a completely bloodless surgical field without fear of damaging fragile or calcified blood vessels. LeGoo also prevents back bleeding from side-branches or collaterals. Because LeGoo temporarily ‘stents’ the vessel and allows for suturing directly through the gel, it facilitates construction of the anastomosis. LeGoo does not need to be removed before completing the anastomosis; upon completion, LeGoo is dissolved by cooling the vessel with ice or cold saline.
For more information: LeGoo will be on display at the Charing Cross Symposium at Pluromed’s booth #18.




Share this item



HOLD THE DATE
Days
Hours
Minutes
Vascular News





Interventional News




Monday, 21 May 2012

Cardiovascular News





 CX Pavilion Sponsors

COOK Medical
Cordis
Gore
Maquet
Medtronic
Terumo
Vascutek

 CX Major Sponsors

Bolton Medical
Covidien
Endologix
GE Healthcare
Tri Vascular

BIBA Medical, 44 Burlington Road, Fulham, London, SW6 4NX.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions